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Background. The extraordinary invasiveness of human glioblastoma multiforme (GBM) contributes to treatment failure and the grim
prognosis of patients diagnosed with this tumor. Consequently, it is imperative to define further the cellular mechanisms that control
GBM invasion and identify promising novel therapeutic targets. Melanoma differentiation associated gene–9 (MDA-9/syntenin) is a
highly conserved PDZ domain–containing scaffolding protein that promotes invasion and metastasis in vitro and in vivo in human mel-
anoma models. To determine whether MDA-9/syntenin is a relevant target in GBM, we investigated its expression in tumor samples and
involvement in GBM invasion and angiogenesis.
Materials. We assessed MDA-9/syntenin levels in available databases, patient tumor samples, and human-derived cell lines. Through
gain-of-function and loss-of-function studies, we analyzed changes in invasion, angiogenesis, and signaling in vitro. We used orthotopic
xenografts with GBM6 cells to demonstrate the role of MDA-9/syntenin in GBM pathogenesis in vivo.
Results. MDA-9/syntenin expression in high-grade astrocytomas is significantly higher than normal tissue counterparts. Forced overex-
pression of MDA-9/syntenin enhanced Matrigel invasion, while knockdown inhibited invasion, migration, and anchorage-independent
growth in soft agar. Moreover, overexpression of MDA-9/syntenin increased activation of c-Src, p38 mitogen-activated protein kinase,
and nuclear factor kappa-B, leading to elevated expression of matrix metalloproteinase 2 and secretion of interleukin-8 with correspond-
ing changes observed upon knockdown. GBM6 cells that stably express small hairpin RNA for MDA-9/syntenin formed smaller tumors and
had a less invasive phenotype in vivo.
Conclusions. Our findings indicate that MDA-9/syntenin is a novel and important mediatorof invasion in GBM and a key regulatorof patho-
genesis, and we identify it as a potential target for anti-invasive treatment in human astrocytoma.
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In the United States, an estimated 69 720 new cases of primary
CNS tumors will be diagnosed in 2013.1 Gliomas, named for
the normal glial cell to which they bear the closest resemblance,
encompass a wide histology of tumors and account for 80% of
malignant primary CNS neoplasms. Over 75% of all gliomas are
astrocytomas, which are composed of neoplastic astrocytes and
range in grade from low-grade pilocytic astrocytoma (grade I) to
high-grade tumors (grade IV, glioblastoma multiforme [GBM]).2
GBM is a notoriously aggressive, proliferative, and invasive tumor
that, despite recent advances in radiation and chemotherapies,
has a 5-year survival rate of ,5%.1 Furthermore, surgical resection
to remove all of the tumor is difficult or impossible because of the
vital nature of the surrounding tissue and is not curative due to the
abilityof single GBM cells to migrate from the primary tumor mass.3
While all higher-grade astrocytic tumors demonstrate diffuse
infiltration, GBM is particularly adept at invading the brain
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parenchyma.4 Rapid growth along myelinated portions leads to
supratentorial bilateral extension of these tumors, notably along
the fornices toward the temporal lobes and across the corpus cal-
losum, leading to a “butterfly glioma” pattern. In addition to track-
ing along myelinated structures, another avenue of invasion is
observed within and along perivascular spaces.5 A detailed un-
derstanding of the involved and layered regulation of glioma inva-
sion is only beginning to form.4 Nonetheless, crucial differences in
how normal glial migration differs from glioma cell migration have
yet to be uncovered.6
To successfully invade the surrounding tissue, a glioma cell
must detach from the primary mass, adhere to and degrade the
extracellular matrix (ECM), and engage processes of cell motility
and contractility.4 After breaking from the primary tumor, glioma
cells adhere to the ECM most often through interactions utilizing
integrins, transmembrane glycoprotein heterodimers. Integrins
associate with an assortment of ECM proteins, including fibronec-
tin, vitronectin, and fibrinogen, and increased expression of integ-
rins can lead to increased cell motility in glioma cells.6 Next,
invading cells use matrix metalloproteinases (MMPs), including
MMP2 and MMP9, to degrade ECM, which can be regulated by the
transcription factor nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB).6 Once a path is cleared, glioma cell loco-
motion relies on the function of actin, responsible for driving the
leading processes of migrating cells, and the dynamics of myosin II,
a major generator of contractile force.7
Melanoma differentiation associated gene–9 (mda-9),8 also
known as syntenin,9 is an intriguing protein with involvement in a
plethora of cellular functions.10 – 13 In addition to roles in cell-cell
and cell-matrix adhesion, MDA-9/syntenin is an integral element
in signal transduction from the cell’s surface to the interior; levels
of MDA-9/syntenin are detectable in all human fetal and adult
tissues and the gene has been shown to be highly homologous
across species.13 mda-9/syntenin was first identified as a biphasic-
expressing gene through subtraction hybridization comparing
human melanoma cells in unaltered and terminally differentiated
states, suggesting a potential role in melanoma pathogenesis.8,14
This view was confirmed by later studies that revealed the in-
fluence of MDA-9/syntenin as a positive regulator of the progres-
sion and metastatic potential of human melanoma through
interactions with c-Src.15 – 18 By facilitating active focal adhesion
kinase (FAK)/c-Src complexes, MDA-9/syntenin amplifies signaling
through a p38 mitogen-activated protein kinase (MAPK)–dependent
pathway, ultimately activating NF-kB and leading to upregulation
of MMP activity. Furthermore, forced expression of MDA-9/synte-
nin results in increased migration by nonmetastatic cancer cells,
and manifests an increasingly polarized distribution of F-actin
and greater pseudopodia formation. In addition to melanoma,
MDA-9/syntenin was found at increased levels in multiple
breast and gastric cancer cell lines and in a single genetically
uncharacterized human glioma cell line, contributing to cell
migration.19,20
In addition to established roles in human melanoma, MDA-9/
syntenin has been shown to be important in gastrulation and
nervous system development. In zebrafish, MDA-9/syntenin was
essential for epiboly and implicated in actin cytoskeleton re-
arrangement.21 In investigations of processes of neural develop-
ment, MDA-9/syntenin was shown to bind neurofascin, SynCAM,
and neurexin, cell adhesion molecules involved in axonal growth
and proper formation of synaptic structures (reviewed by Das
et al12). One of the earliest genes expressed during neuronal differ-
entiation, serine/threonine kinase Unc51.1, uses MDA-9/syntenin
as a scaffold, as does Rab5 GTPase, a regulator of endocytosis
and membrane organization during axon outgrowth.22
The current studies demonstrate that MDA-9/syntenin expres-
sion is increased in multiple neuroepithelial tumors of the CNS. Fo-
cusing on glioma cell lines, we demonstrate that expression of
MDA-9/syntenin is elevated compared with controls and correlates
with increasing tumor grade in patient samples. Additionally, we
characterize MDA-9/syntenin as a driver of glioma motility and in-
vasion, acting through a c-Src–dependent pathway leading to the
activation of NF-kB.
Materials and Methods
Construction of Plasmids, Adenoviruses, and Stable Cell Lines
Small hairpin (sh)RNA for mda-9/syntenin (shmda-9/syntenin) has been
constructed with pSilencer hygro expression vectors according to the man-
ufacturer’s protocol (Ambion). Specific hairpin small interfering (si)RNA oli-
gonucleotides (sense 5′-GATCCGCGGATGGCACCAAGCATTTTCAAGAGAAATG
CTTGGTGCCATCCGCTTTTTTGGAAA-3′ and antisense 5′-AGCTTTTCCAAAAAA
GCGGATGGCACCAAGCATTTCTCTTGAAAATGCTTGGTGCCATCCGCG-3′) were
annealed and ligated to pSilencer vector by T4 DNA ligase. The genomic se-
quence of mda-9/syntenin was amplified by PCR using genomic DNA as
template and primers, sense: 5′-CTGCAAAAATGTCTCTCTATCC-3′ and anti-
sense: 5′-GGTGCCGTGAATTTTAAACCTCAG-3′. The PCR product was cloned
into pREP4 expression vectors, from where it was digested and released
with Xho and BamH1 and subcloned into the pcDNA3.1 (+hygro) (Invitro-
gen). The DNA fragment (702 bp) containing the U6 promoter followed by
oligonucleotide encoding shRNA designed for the mda-9/syntenin gene
was isolated from EaeI-digested pSilencer–shmda-9 plasmid and then
cloned into the NotI site of pShuttle (pSh) plasmid generating pshmda-9-
shuttle vector. To construct the shuttle vector pShCMV–MDA-9, BamHI
and EcoRV DNA fragment (990 bp) containing the mda-9/syntenin gene
was isolated from plasmid p0tg-CMV–MDA-9 22 and cloned between
BglII and EcoRV sites downstream of the cytomegalovirus (CMV) promoter
in plasmid pSh-CMV. The shuttle plasmids were recombined with genomic
DNA of Ad.5/3.Luc1 vector as we previously described23 to derive plasmids
pAd.5/3–shmda-9 or pAd.5/3–mda-9. The resultant plasmids were
cleaved with PacI to release the recombinant adenovirus genomes and
then transfected to human embryonic kidney (HEK)–293 cells to rescue
the corresponding Ad.5/3-based vectors. The rescued viruses were
upscaled using HEK-293 cells and purified by cesium chloride double ultra-
centrifugation using standard protocol, and the titers of infectious viral par-
ticles were determined by plaque assay using HEK-293 cells as described.24
Alternate siRNA sequences were obtained through Qiagen with the fol-
lowing sequences: 5′-TTGACTCTTAAGATTATGTAA-3′ (simda-9 #3) and
5′-TGGGATGGTCTTAGAATATTT-3′ (simda-9 #4). Ad.5/3 shmda-9 resistant
mda-9/syntenin was constructed using the following primer sequences:
forward 5′-GCCTGCTTTTATCTTTGAACATATTATTAAGCGAATGAAGCCTAGTATA
ATGAAAAGCCTAATGGACCACACCATTCCTGAG-3′ and reverse: 3′-CGGACGA
AAATAGAAACTTGTATAATAATTCGCTTACTTCGGATCATATTACTTTTCGGATTACCT
GGTGTGGTAAGGACTC-5′.
Cell Lines, Cell Culture, and Human Tissue Samples
Human malignant glioma cells U87, U251, and T98G as well as grade III
astrocytoma lines Sw1088 and Sw1783 were purchased from the American
Type Culture Collection. Human primary GBM6 cells were described previ-
ously and were provided by Dr C. David James (University of California,
San Francisco).25 Cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) + F12 supplemented with 10% fetal calf serum in a
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378C incubator supplemented with 5% CO2. Primary human fetal astro-
cytes (PHFAs) were obtained from preterm abortions as previously
described with institutional review board approval, and human telomerase
reverse transcriptase (h-TERT)– immortalized (IM) PHFAs were produced
and cultured as described.26 All cells were routinely screened for mycoplas-
mal contamination. Specimens of human primary brain tumors were col-
lected from subjects who underwent surgical removal of their brain
tumors at the Department of Neurosurgery,New York Presbyterian Hospital,
Columbia University. All subjects were informed of the nature and require-
ments of the study and provided written consent to donate their tissues for
research purposes. Tumor specimens of all histological types and grades of
primary brain tumors were collected, snap frozen, and stored in the tumor
bank following the protocol approved by an institutional review board.
Preparation of Whole-cell Lysates and Western Blotting
Analysis
Preparation of whole-cell lysates and western blotting analysis were done
as described.27 For densitometric evaluation, X-ray films were scanned
and analyzed with ImageJ software (National Institutes of Health [NIH]).
Antibodies and Reagents
Antibodies against IkBa, phospho-IkBa (Ser32/36), p38MAPK, phospho-
p38MAPK (Thr180/Tyr182), Src, and phospho-Src (Tyr 416) were obtained
from Cell Signaling. MMP2, b-actin, and a-tubulin were obtained from
Abcam, and MDA-9/syntenin from Abnova. MDA-9/synteninused for immu-
nohistochemistry (HPA023840) was purchased from Sigma-Aldrich, as was
fibronectin, and SB203580 was purchased from Calbiochem. Inhibitor of
kappa B kinase (IKK) inhibitor was kindly provided by Dr Albert S. Baldwin,
Jr (University of North Carolina, Chapel Hill).
Immunohistochemistry
A portion of the frozen tumor specimen was fixed in phosphate-buffered
formalin and preserved as paraffin sections following standard procedure
for the maintenance of histological structure. Paraffin-embedded sections
were dewaxed and rehydrated through incubations in xylene and a gradient
series of alcohol. Antigen retrieval was processed in 10 mM citric acid (pH
6.0) with microwave treatment for 20 min. Endogenous hydrogen peroxid-
ase was quenched with 3% H2O2 for 20 min. After blocking nonspecific
binding sites with 5% normal sera, the sections were incubated overnight
with antibody. The sections were incubated with appropriate biotinylated
secondary antibody and subsequently with avidin-biotin-peroxidase
complex (Vector Elite, Vector Laboratories). Colorimetric reactions were
developed by incubation in diaminobenzidine substrate (0.02% diamino-
benzidine, 0.005% hydrogen peroxide) and counterstained with 10%
Harris’ hematoxylin. Hematoxylin and eosin staining was conducted follow-
ing a standard protocol.17 The images were analyzed under the Olympus
BX41 microscope system equipped with a DP25 digital camera and soft-
ware. Tissue microarray CNS2081 was purchased from US Biomax.
Upon analyzing MDA-9/syntenin staining of normal brain and lymph
node tissue (positive control), Dr Christine Fuller scored the CNS2081 tissue
microarray on a scale of 0–3. Average scores for each of the 104 cores were
used to calculate mean scores for each tissue group. Scores were compared
with cancer adjacent tissue and normal brain tissue using Student’s t-test.
Invasion and Migration Assays
Invasion was measured using 24-well BioCoat cell culture inserts (BD Bios-
ciences) with an 8-mm-porosity polyethylene terephthalate membrane
coated with Matrigel Basement Membrane Matrix (100 mg/cm2). Briefly,
the Matrigel was allowed to rehydrate for 2 h at 37C by adding warm,
serum-free DMEM. The wells of the lower chamber were filled with
medium containing 5% fetal bovine serum. Cells (5×104) were seeded in
the upper compartment (6.25-mm membrane size) in serum-free
medium. The invasion assay was done at 378C in a 5% CO2 humidified incu-
bator for 18 h. At the end of the invasion assay, filters were removed, fixed,
and stained with the Diff-Quick Staining kit (IMEB). Cells remaining on the
upper surface of the filters were removed by wiping with a cotton swab,
and invasion was determined by counting the cells that migrated to the
lower side of the filter using at least 5 fields per insert at 100×magnification.
Wound healing scratch motilityassays were done as described previously.17
Data from triplicate experiments were expressed as mean+95% confi-
dence interval (CI).
Anchorage-independent Growth Assays in Soft Agar
Anchorage-independent growth assays were performed byseeding 5×104
cells in the CytoSelect Cell Transformation Assay (Cell Biolabs) in 24-well
plates according to the manufacturer’s instructions. Colonies were counted
12 days after seeding and analyzed using ImageJ colony counter (NIH).
The data from triplicate wells were expressed as mean+95% CI.
Preparation of Conditioned Media
Conditioned media were harvested from an overnight culture of plated cells
in serum-free DMEM + F12 media, filtered with 0.2 mM filters and further
concentrated 10-fold on an Amicon Ultra centrifugal filter –3 K (Millipore).
Virus Infections and Reporter Assays
Viral infection conditions and protocols were performed as delineated pre-
viously.17 Luciferase reporter assays were performed using 2×105 cells
infected with either Ad.5/3-vec or Ad.5/3–mda-9. Twenty-four hours post-
infection, cells were transfected with an NF-kB–responsive luciferase re-
porter construct with Lipofectamine 2000 as described.16,17 Forty-eight
hours after transfection, cells were trypsinized and plated on fibronectin-
coated surfaces (10 mg/mL) in serum-free medium for 1 h. Cell lysates
were harvested and luciferase activity was measured using a Dual-
Luciferase Reporter Assay system (Promega) according to the manufac-
turer’s instructions. Luciferase activity was normalized by Renilla activity,
and data represent the average of triplicates+SD.
Human Angiogenesis Arrays and Chicken Chorioallantoic
Membrane Assays
Using conditioned media, equal amounts of protein (500 mg) in 100-mL
samples were assayed using human angiogenesis antibody arrays (R&D
Biosystems) and processed according to the manufacturer’s instructions.
Chicken chorioallantoic membrane (CAM) assays were performed using
9-day-old chick embryos; cells were seeded on the CAM surface according
to established protocols.28 One week after inoculation, the neovasculature
was examined and photographed.
Xenograft Studies in Athymic Nude Mice
Subcutaneous xenografts were established in the flanks of athymic nude
mice (4- to 5-wk-old female mice, from Charles River) using 1×105 cells
and followed for 3 weeks. Tumor volume was measured 3 times weekly
with a caliper and calculated using the following formula: p/6× larger
diameter× (smaller diameter).2 Postsacrifice, the tumors were resected,
weighed, and preserved for immunohistochemical staining.
Intracranial Implant of GBM6 Cells in Nude Mice
Athymic female NCr-nu/nu mice (National Cancer Institute–Frederick)
weighing 20 g were used for this study. Mice were maintained under
pathogen-free conditions in facilities approved by the American Association
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for Accreditation of Laboratory Animal Care and in accordance with current
regulations and standards of the US Department of Agriculture, the US De-
partment of Health and Human Services, and the NIH. At least 10 mice per
group were utilized. Mice were anesthetized through i.p. administration of
ketamine (40 mg/kg) and xylazine (3 mg/kg) and immobilized in a stereo-
tactic frame (Stoelting). A 24-gauge needle attached to a Hamilton
syringe was inserted into the right basal ganglia to a depth of 3.5 mm
and then withdrawn 0.5 mm to make space for tumor cell accumulation.
The entry point at the skull was 2 mm lateral and 1 mm dorsal to the
bregma. Intracerebral injections of 1.5×104 cells in 2 mL per mouse were
completed over 10 min using an automated injector (Stoelting). The skull
opening was enclosed with sterile bone wax, and the skin incision was
closed using sterile surgical staples.
Database Mining
We surveyed 2 publicly available databases: (i) The Cancer Genome Atlas
(TCGA) that combined low- grade glioma (LGG) and GBM datasets
(https://tcga-data.nci.nih.gov/tcga/), generated using Illumina HiSeq
2000 RNA Sequencing, and (ii) the National Center for Biotechnology Infor-
mation Gene Expression Omnibus (NCBI-GEO) dataset GSE4290,29 derived
by using the Affymetrix HG U133 Plus 2 platform. The datasets were
obtained through the NCBI-GEO and the University of California, Santa
Cruz Cancer Genomics Browser30 websites, respectively, and data were
analyzed using the Gene-E (Broad Institute) and JMP Pro 10 (SAS) analytic-
al/statistical programs.
Statistical Analysis
The data are reported as the mean+SD of the values from 3 independent
determinations, and significance analysis was performed using the Student’s
t-test in comparison with corresponding controls. P , .05 was considered
statistically significant. Survival curves were analyzed using Cox proportional
hazards survival regression (http://statpages.org/prophaz.html).
Results
Elevated MDA-9/syntenin Expression Is Common
in Neuroepithelial Tumors of the CNS and Correlates
With Astrocytoma Tumor Grade
Given the increased expression of MDA-9/syntenin observed in
human melanoma, we asked whether similar trends were evident
Fig. 1. mda-9/syntenin is overexpressed in glioma clinical samples and cell lines. (A) mda-9/syntenin expression in glioma tumor grade compared with
normal tissue using the NCBI-GEO GSE4290 dataset. (B) mda-9/syntenin expression in varying grades of glioma tumors using the TCGA LGG and GBM
dataset. (C) Kaplan–Meier survival plot comparing survival time according to mda-9/syntenin expression. High expression: mda-9/syntenin levels
above median. Low expression: mda-9/syntenin levels below median. (D) mda-9/syntenin expression in various cell lines. (E) Representative images of
mda-9/syntenin expression in normal and tumor samples. ** P , .05.
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in primary brain tumors. To answer this question, we analyzed TCGA
combining LGG and GBM datasets and the NCBI-GEO dataset.29 As
both datasets indicate (Fig. 1A and B), the mda-9/syntenin transcrip-
tion level, on average, increases as tumor grade progresses (ANOVA
test, P , .0001 in both datasets). In the GSE4290 dataset, nontumor
cases were obtained from epilepsy patients. As of this writing, refer-
ence (normal) cases are not included inthe LGGand GBM datasets of
TCGA.
Increased expression of mda-9/syntenin appears to be a clinic-
ally important phenomenon, as shown by analysis of TCGA patient
survival segregated by expression (Fig. 1C). Patients with gliomas
expressing above median levels of mda-9/syntenin show a marked
decrease in survival compared with those with below median
mda-9/syntenin (Kaplan–Meier survival analysis, P , .0001 in both
log-rank and Wilcoxon statistical tests).
To validate these observations from genomic datasets, we ana-
lyzed a tissue microarray consisting of 104 cores, including tumor,
cancer adjacent normal, and normal tissues. In these samples,
specimens were classified according to World Health Organization
grades of brain tumors,2 and strength of MDA-9/syntenin staining
was scored (Table 1). We found that astrocytomas of all grades had
significantly higher MDA-9/syntenin expression than normal tissue
counterparts (Fig. 1E). We determined that in human astrocyto-
mas taken together, similar to the pattern observed in human
melanomas, elevated MDA-9/syntenin was more common in high-
grade tumors. Protein expression of MDA-9/syntenin was verified
by western blotting in 46 specimens from surgically removed
primary brain tumors. When compared with samples obtained
from normal brain tissue, which expectedlyshowed low but detect-
able levels, tumor tissue showed high expression of MDA-9/synte-
nin more frequently (Supplementary Figs. 1, 2). Cell lines used in
vitro were then analyzed for MDA-9/syntenin expression level.
Barely detectable levels were observed in PHFAs, and slightly
higher levels were found in h-TERT IM-PHFA cells, while robust ex-
pression was seen in GBM lines U87MG, T98G, and U251 (Fig. 1D).
MDA-9/syntenin Protein Level Correlates With Changes
in the Invasive Ability of Astrocytoma Cells
Next, we determined whether manipulating MDA-9/syntenin ex-
pression could lead to changes in invasion in vitro. Accordingly,
MDA-9/syntenin expression was reduced in GBM cell lines T98G
and U87MG using an adenovirus expressing shRNA targeted to
mda-9/syntenin. Cells treated with Ad.5/3–shmda-9 had approxi-
mately a 5-fold decrease in invasive ability compared with vector
(Ad.5/3-con sh)-treated cells (P , .001; Fig. 2A). Conversely,
MDA-9/syntenin was overexpressed using adenovirus (Ad.5/3–
mda-9) in 3 cell lines that normally express low levels: IM-PHFA,
Sw1783, and GBM5. When compared with cells infected with
vector alone (Ad.5/3-vec), cells that overexpressed MDA-9/
syntenin after Ad.5/3–CMV–mda-9 (Ad.5/3–mda-9) treatment
invaded at significantly higher rates, with 2-, 3-, and 5-fold
increases (IM-PHFA, Sw1783, GBM5), respectively, in invasion (P ,
.001; Fig. 2B). To account for the possibility of off-target effects,
we used multiple alternative siRNA sequences for knockdown
experiments and an mda-9/syntenin construct designed to be re-
sistant to Ad.5/3–shmda-9. Similar results were observed when
using alternative siRNA sequences. Protein levels and invasion
were reduced at levels equivalent to those observed using Ad.5/
3–shmda-9 (Supplementary Fig. 3). Additionally, a plasmid con-
struct with sequences mutated to be resistant to the targeting
of our adenoviral vector rescued invasiveness in the presence of
Ad.5/3–shmda-9 (Supplementary Fig. 4).
MDA-9/syntenin Signaling Is c-Src Dependent and
Activates NF-kB Through the p38MAPK Pathway
To determine the mechanism by which MDA-9/syntenin provokes
changes in downstream signaling, we analyzed protein levels in
astrocytoma cells after MDA-9/syntenin manipulation (Fig. 3A).
In previous studies, c-Src was found to be an important interacting
partner and effector of MDA-9/syntenin signaling, contributing to
a metastatic phenotype in human melanoma.15 – 18 Indeed, over-
expression of MDA-9/syntenin in Sw1783 and GBM5 cells leads to
increased levels of activated Src. Conversely, reducing MDA-9/syn-
tenin in T98G and U87MG cells lowers phosphorylated Src levels.
Initiation of c-Src signaling can lead to activation of the p38MAPK
pathway and ultimately to NF-kB activation and the transcription
of cellular genes involved in invasion. Phosphorylated p38MAPK
was increased upon MDA-9/syntenin overexpression in Sw1783
and GBM5 cells. A decrease in activated p38MAPK was also
observed after knockdown of MDA-9/syntenin. The phosphoryl-
ation of IkBa, which normally maintains NF-kB in an inactive
state in the cytoplasm, targets it for degradation, leaving NF-kB
free to translocate into the nucleus. When MDA-9/syntenin is over-
expressed, there is an increase in phosphorylated IkBa and a con-
comitant increase in MMP2, a known target of NF-kB. Likewise,
infection with Ad.5/3–shmda-9 reduced phosphorylated IkBa
and MMP2.
As in previous studies performed in human melanoma,16 we
found that MDA-9/syntenin bound to Src in GBM cells by immuno-
precipitation (Supplementary Fig. 5). To determine whether the in-
crease in invasion correlating with MDA-9/syntenin overexpression
was dependent on c-Src, we transfected plasmids encoding
wild-type or dead kinase Src, which acts as a dominant negative
protein, along with a control plasmid or mda-9/syntenin into








Astrocytoma grade I 2.67+0.52 6 .007 .077
Astrocytoma grade II 2.82+0.40 11 .0002 .007
Astrocytoma grade III 3.00+0.00 7 .001 .007
GBM 2.75+0.46 8 .001 .028
Oligodendroglioma 3.00+0.00 5 .003 .023
Malignant
oligodendroglioma
2.83+0.29 3 .028 .120
Ependymoma 1.33+0.58 3 .608 .491
Malignant ependymoma 2.80+0.45 5 .008 .061
Medulloblastoma 2.80+0.42 10 .0003 .011
CAT 0.94+1.21 8 1.000 .165
NT 1.79+0.99 7 .165 1.000
Right columns compare average tumor section scores with average scores
for cancer-adjacent normal tissue (CAT) or normal brain tissue (NT).
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GBM5 cells. In this experiment, the enhanced invasion we observed
when overexpressing MDA-9/syntenin was mitigated when coex-
pressing the dominant negative c-Src protein (Fig. 3B, Supplemen-
tary Fig. 6A).
To further investigate the activation of NF-kB following forced
MDA-9/syntenin expression, we transfected Sw1783 cells with a
plasmid producing luciferase under the control of a promoter
with NF-kB binding sites. Consequently, we expected increased lu-
minescence in cells subsequently treated with Ad.5/3–mda-9
compared with those treated with Ad.5/3-vec. As anticipated,
examining cells with the reporter plasmid that overexpressed
mda-9/syntenin, we observed a .2.5-fold induction of NF-kB activ-
ity compared with vector-infected cells (Fig. 3C).
Finally, we employed pharmacological inhibitors in vitro to
confirm the pathway through which mda-9/syntenin exerts its
effects. Using IM-PHFA and Sw1783 cell lines, cultures were
infected with an Ad.5/3-vec or Ad.5/3–mda-9. These cells were
then treated with dimethyl sulfoxide, IKK inhibitor, or SB203580,
a p38MAPK inhibitor, and subsequently analyzed for invasive
potential. As expected, overexpression of mda-9/syntenin leads
to significant increases in invasion compared with vector-treated
cells (Fig. 3D, Supplementary Figs. 6B and C). We would expect
that if MDA-9/syntenin performed its invasion signaling through a
pathway outside of the p38MAPK–NF-kB axis, pharmacological in-
hibition of these proteins would have minimal effect. Notably, both
the IKK inhibitor and SB203580 abrogated the invasion gains in
cells overexpressing mda-9/syntenin.
GBM Cells Expressing shmda-9 Show Marked Reductions
in Invasion, Tumorigenesis, and Angiogenesis
To further explore the effects of mda-9/syntenin knockdown,
clones that stably express shmda-9 were produced in GBM6 cells,
with substantial knockdown achieved in several of the isolated col-
onies (Fig. 4A). Compared with the normally invasive control clones,
GBM6–shmda-9 clones exhibited 2.5- to 4-fold decreases in inva-
sive ability (Fig. 4B).
The invasive capacity of GBM cells depends on both digestion of
ECM, as monitored by Matrigel invasion assays, and the locomotive
abilityof these cells once a path is cleared. Thus, the migration rates
Fig. 2. MDA-9/syntenin regulates astrocytoma invasion. (A) Knockdown of MDA-9/syntenin leads to decreases in invasion. (Left) Protein expression
of MDA-9/syntenin after viral infection, 200 plaque-forming unit (pfu)/cell. (Center) Representative images of Matrigel invasion in GBM cell lines T98G
and U87. Decreases in MDA-9/syntenin expression correspond with inhibition of invasion. (Right) Invasion quantified using 5 fields per triplicate well.
(B) Overexpression of MDA-9/syntenin leads to increases in invasion. (Left) Protein expression of MDA-9/syntenin after viral infection, 100 pfu/cell.
(Center) Representative images of Matrigel invasion in IM-PHFA, Sw1783, and GBM5 lines. Increases in MDA-9/syntenin expression leads to enhanced
invasion. (Right) Invasion quantified using 5 fields per triplicate well. ** P , .01.
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of GBM6–shmda-9 clones were analyzed by quantifying gap
closure after 18 and 24 h. As a result of reduced MDA-9/syntenin
levels, gap closure was reduced by as much as 50% in GBM–
shmda-9 cells compared with GBM6-control (Fig. 4C).
Anchorage-independent growth is an established marker for
transformation and a tumorigenic phenotype in specific cancer
cell types. To determine the effect of MDA-9/syntenin knockdown
on the ability of transformed cells to grow in an anchorage-
independent environment, GBM6-control and shmda-9 clones
were seeded in a soft agar transformation assay (Cell Biolabs).
Control GBM6 cells readily formed large and numerous colonies
after 8 days of growth in soft agar. Reduced levels of MDA-9/synte-
nin in GBM6–shmda-9 cells led to a decrease in the number and
size of the colonies formed (Fig. 4D). Consequently, MDA-9/synte-
nin has a significant effect on the ability of transformed GBM
cells to grow in an anchorage-independent environment in vitro.
Tumorigenic capacity in vivo was then analyzed by injecting 105
GBM6-control or GBM6–shmda-9 cells subcutaneously into
athymic nude mice. Tumors were measured 3 times weekly, and
after 21 days the mice were sacrificed and the tumors resected
and weighed. GBM6-control cells formed consistently larger
tumors by volume and weight compared with their MDA-9/
syntenin-depleted counterparts (Fig. 5A). Because GBM6–
shmda-9 clones show no differences in proliferation rate in vitro
(Supplementary Fig. 7), differences in tumor size could be due to
changes in angiogenic ability caused by the knockdown of
MDA-9/syntenin. To test this hypothesis, we knocked down
MDA-9/syntenin by Ad.5/3–shmda-9 viral infection of T98G GBM
cells and harvested conditioned media. By means of a CAM
assay, we observed marked differences in blood vessel develop-
ment when exposed to control GBM conditioned media (T98G
cells infected with Ad.5/3-vec) compared with media from Ad.5/
3–shmda-9 infected T98G cells. Less microvessel development
and fewer branch points were evident in membranes exposed to
media from knockdown cells (Fig. 5B). Upon analysis using an
angiogenic protein array, substantial reductions in the levels of
secreted interleukin (IL)-8 were observed (Fig. 5C). These data
are corroborated by similar trends in mRNA levels of IL-8 in T98G
cells, as well as increased mRNA levels in IM-PHFA cells overexpres-
sing MDA-9/syntenin (Fig. 5D). Moreover, secreted IL-8 levels were
increased in the conditioned media of IM-PHFA cells infected
with Ad.5/3–mda-9 as measured by ELISA. Likewise, decreased
IL-8 was detected from MDA-9/syntenin-depleted T98G cells
(Fig. 5E). In total, these in vitro and in vivo data demonstrate the
crucial role that MDA-9/syntenin plays in tumor formation and
angiogenesis.
Fig. 3. MDA-9/syntenin activates NF-kB through an Src, P38MAPK-dependent pathway. (A) Protein expression following overexpression (left columns) or
knockdown (right columns) in the indicated cell lines. b-actin is used as an internal control for protein loading. (B) Results from Matrigel invasion in GBM5
cells following Ad.5.3-vec or Ad.5/3–mda-9 infection and transfection with vector, wild-type Src (WT), or dominant negative (DN) dead kinase Src. Invasion
quantified using 5 fields per triplicate well. (C) Fold NF-kB induction in Sw1783 cells after MDA-9/syntenin overexpression compared with vector control.
NF-kB induction measured using 3kB-Luc transfection, a plasmid containing 3 tandem NF-kB binding sites upstream of the luciferase gene. (D) Results
from Matrigel invasion in IM-PHFA and Sw1783 cells following Ad.5.3-vec or Ad.5/3–mda-9 infection and treatment with dimethyl sulfoxide, IKK
inhibitor, or SB203580 (P38MAPK inhibitor). Invasion quantified using 5 fields per triplicate well. ** P , .01.
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Knockdown of MDA-9/syntenin Leads to Changes in Tumor
Properties in an Orthotopic Tumor Model of Glioma
To provide a more authentic tumor microenvironment and to
further explore the role of MDA-9/syntenin in invasion, we
employed an orthotopic xenograft model in which 15 000 cells
were stereotactically injected intracranially into athymic nude
mice. The mice were monitored for neurological symptoms such
as paralysis, seizures, weight loss, and lethargy and were sacrificed
according to a protocol approved by the Institutional Animal Care
and Use Committee. The survival times for the GBM6–shmda-9
group were significantly longer compared with the GBM6-control
group by chi-square analysis (P¼ .015; Fig. 6A). Postmortem,
brain and tumor tissue were collected and sectioned for immuno-
histochemical staining. GBM6–shmda-9 tumors retained a lower
level of MDA-9/syntenin expression, although both control
Fig. 4. Stable MDA-9/syntenin knockdown in GBM results in decreased invasion, migration, and anchorage-independent growth. (A) MDA-9/syntenin
protein levels were decreased by stable expression of shmda-9 in GBM6 cells. (B) Results from Matrigel invasion of GBM6–shmda-9 clones. Invasion
quantified using 5 fields per triplicate well. (C) (Left) Wound healing assay after 18 and 24 h in control and shmda-9 GBM6 Cl 1 and Cl 3. (Right)
Quantification of triplicate wound healing scratch assays as quantified using ImageJ. a differs from b (P , .01), and c differs from d (P , .01).
(D) (Upper) Representative images of anchorage-independent growth in soft agar using GMB6-control and shmda-9 clones. (Inset) Higher
magnification illustrating the differences in colony size. (Lower) Quantification of colony number (left) and size (right) using ImageJ. ** P , .01.
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tumors and GBM6–shmda-9 tumors showed localized increases in
MDA-9/syntenin at the tumor borders (Fig. 6B). Additionally,
GBM6-control tumors exhibited substantially greater CD31 expres-
sion compared with GBM6–shmda-9 tumors, supporting a role for
MDA-9/syntenin in GBM angiogenesis (Fig. 6B). Furthermore, note-
worthy differences were found in the invasion patterns of tumors
formed from GBM6-control cells and tumors from GBM6–shmda-
9 cells. GBM6-control tumors were notable for fingerlike projections
and tumor nests separate from the main body of the tumor. Add-
itionally, control tumors displayed prominent infiltration along
Virchow-Robin spaces and conspicuous leptomeningeal invasion
(Fig. 6C, upper panels). Alternatively, tumors formed from GBM6–
shmda-9 cells had minimal focal tumor invasion into surrounding
brain parenchyma, much less than that observed in control
tumors, with the majority of tumor having well-demarcated
margins (Fig. 6C, lower panels). This provides additional data relative
to the critical role of MDA-9/syntenin in GBM invasion and points
to it as a possible target to reduce infiltration of GBM cells into
surrounding brain tissue.
Discussion
We presently provide definitive evidence for a role of MDA-9/synte-
nin in mediating astrocytoma invasion and pathogenesis. Earlier
studies implicated MDA-9/syntenin in numerous cellular functions
and found its expression to be particularly relevant in cancer
metastasis. While systemic metastasis of astrocytoma is highly
uncommon, the propensity for local invasion of the brain paren-
chyma leads to challenges in treatment and inevitable tumor
recurrence.3 We found MDA-9/syntenin to be overexpressed in
astrocytoma with a correlation with tumor grade (Fig. 1A and B),
as grade IV astrocytomas (GBM) had the highest level of MDA-9/
syntenin expression. Uncovering new targets for treatment in
these tumors will be particularly important, as median survival
remains about 1 year despite aggressive therapy.3 Our invasion
studies indicated that MDA-9/syntenin was a significant factor in
determining invasiveness and migratory capacity of astrocytoma
cells, as both forced overexpression and knockdown of MDA-9/
syntenin led to alterations in invasive ability. Given the involvement
Fig. 5. MDA-9/syntenin knockdown decreases tumor size in vivo and angiogenesis in vitro. (A) (Left) Tumor volume from subcutaneous injection of GBM6
control and shmda-9 expressing clones. (Right) Weight of resected subcutaneous tumors after 21 days. a differs from b (P , .01) (B) Representative images
from CAM assay using T98G cells treated with vector or Ad.5/3–shmda-9. The proliferation of the smallest vessels (arrow) is decreased with knockdown of
MDA-9/syntenin. (C) IL-8 expression in conditioned media from treated T98G cells as measured by angiogenesis protein array. (D) Real-time PCR for IL-8
mRNA using IM-PHFA and T98G lines following the indicated treatments. (E) ELISA quantification of IL-8 protein in IM-PHFA and T98G conditioned media.
Media from Ad.5/3–shmda-9 treated cells is normalized to Ad.5/3-con sh treated cells. * P , .05, ** P , .01.
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of MDA-9/syntenin in crucial early stages of development in the
CNS, this suggests that MDA-9/syntenin may be an important
genetic component in less differentiated precursor cells, with
which glioma cells share remarkable similarities, notably the
ability of single cells to migrate throughout the brain.31
An essential aspect of tumor migration and invasion is the inter-
action of single cells with the ECM. Vital contributors in these inter-
actions include one of the most important groups of adhesion
molecules in glioma migration and invasion, the integrins, which
act as signal mediators and anchors to the ECM.32 Specifically,
high expression of the integrin b1 subunit correlates with invasive
behavior in glioma.33 Immunoprecipitation ofb1 integrin in melan-
oma and breast cancer revealed that fibronectin interactions
increased FAK–c-Src–MDA-9/syntenin signaling complexes,
shown to be important regulators of the migration and invasion
machinery.34,35 We document that in astrocytoma, MDA-9/synte-
nin expression leads to c-Src activation and downstream effects on
the p38MAPK pathway, resulting in enhanced invasion. Further-
more, MDA-9/syntenin has been linked to a key mediatorof integrin
and signaling of phosphatidylinositol-3 kinase (PI3K): integrin
linked kinase (ILK).34 ILK is a serine/threonine kinase that acts as
a molecular tether point, can regulate protein-protein interactions,
and coordinates the organization of the actin cytoskeleton.36 Con-
spicuously, phosphatase and tensin homolog, inactivated in a
large percentage of high-grade astrocytomas,37 can inhibit the ac-
tivity of ILK in addition to PI3K.38,39
NF-kB is activated through overexpression of MDA-9/syntenin,
and conversely it can be inhibited through knockdown of MDA-9/
syntenin. Syndecan-1, a member of a major group of cell surface
proteoglycans, is overexpressed in GBM samples and may be regu-
lated by NF-kB.40 This serves as another possible link between
MDA-9/syntenin and glioma, as one of the earlier observations of
MDA-9/syntenin came through its identification as binding the
cytoplasmic domain of syndecans.9 Additionally, pharmacological
inhibition of downstream c-Src effectors abrogates the invasion
gains accrued through MDA-9/syntenin overexpression. Upstream,
c-Src has been linked to an important and common alteration
found in GBM, the amplification or mutation of epidermal growth
factor receptor (EGFR), giving credence to the possibility of MDA-
9/syntenin playing a role in this important signaling pathway.41 –
44Moreover, in a recent study, a physical interaction and colocaliza-
tion of MDA-9/syntenin and EGFR was evident in human urothelial
cell carcinoma cell lines and primary tumors.45
While anti-angiogenic therapy currently exists for high-grade
astrocytoma, these tumors have been shown to evade cell death
through hypoxia-induced autophagy, adapting to therapy through
induction of hypoxia-inducible factor (HIF)–1a.46 MDA-9/syntenin
induction leads to HIF-1a expression in human melanoma (data
not shown). IL-8 has proven to be a particularly important cytokine
in glioma biology. Mutant EGFR signaling acts through NF-kB to
induce secretion of IL-8, leading to an enhanced xenograft neovas-
cularization.47 Additionally, IL-8 is a mediator of invasion in gliomas,
also acting through the NF-kB pathway.48 The angiogenic effect of
MDA-9/syntenin in glioma deserves further exploration, as another
recent study implicated the syndecan–MDA-9/syntenin–Alix axis
in the biogenesis of exosomes, which can be secreted from tumor
cells and contain mRNA and proteins.49 In GBM, exosomes have
been shown to contain translatable mRNA and can contribute to
growth and angiogenesis. In addition to the clinical importance of
MDA-9/syntenin in patient survival demonstrated in Fig. 1C, mining
the National Cancer Institute’sRepositoryofMolecular BrainNeopla-
sia Data database corroborated this finding in human glioma
Fig. 6. MDA-9/syntenin knockdown improves survival and reduces, invasion, and angiogenesis in vivo. (A) Survival time for mice injected with GBM6-control
or GBM6–shmda-9 Cl 3 (P¼ .0086). (B) MDA-9/syntenin and CD31 protein levels from GBM6-control tumors (upper and GBM–shmda-9 tumors lower).
Insert 400× magnification. (C) H&E staining from tissue collected from GBM6-control (top row) and GBM–shmda-9 tumors (bottom row). (Upper left)
GBM6-con. Note tumor invasion surrounding brain parenchyma, with fingerlike projections and tumor nests apart from the main tumor mass showing
infiltration along Virchow-Robin spaces (arrows). (Upper right) GBM6-con. Note leptomeningeal invasion (arrowhead). (Lower left) GBM6–shmda-9.
Very focal leptomeningeal invasion compared with control (arrow). (Lower right) GBM6–shmda-9. Minimal focal tumor invasion into surrounding brain
parenchyma (arrowhead) with a largely demarcated margin.
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patients. In GBM patients with mda-9/syntenin upregulated .2.0×,
survival was significantly shorter (P¼ .0016). Furthermore, in all
glioma patients with mda-9/syntenin upregulated .2.0×, survival
was again significantly reduced (P¼ 6.0×1025).50
Through our in vivo studies, we demonstrate that MDA-9/
syntenin is a major contributor to the deadliest aspect of GBM
pathology, invasion. Combined with our analysis of patient
samples and in vitro data, we propose that MDA-9/syntenin
could prove to be a valuable target for the treatment of high-
grade glioma.
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